Study warns US pharmaceutical policies could cost Swiss industry billions by 2040

Study on US policies warns of billions in losses for Swiss pharma industry

US pharmaceutical policy could prove costly for Switzerland. An industry-backed study estimates that potential losses could reach almost CHF95 billion ($117 billion) by 2040 and warns of consequences for patients. An analysis commissioned by the pharmaceutical industry association Interpharma has examined the potential impact of US pharmaceutical policy on Switzerland. The study by the research institute BAK Economics highlights various possible scenarios, Interpharma announced on Thursday. T...

By swissinfo.ch